Hans H Wandall

Title: Innovations and Contributions of Hans H Wandall

Introduction

Hans H Wandall is a notable inventor based in Charlottenlund, Denmark. He has made significant contributions to the field of cancer research through his innovative patents. With a total of six patents to his name, Wandall's work focuses on the development of antibodies and methods for cancer detection and therapy.

Latest Patents

Wandall's latest patents include "Anti-glyco-MUC1 antibodies and their uses." This patent relates to antibodies that specifically bind to a cancer-specific glycosylation variant of MUC1, along with related fusion proteins and antibody-drug conjugates. These innovations are aimed at enhancing cancer therapy. Another significant patent is "CORE3-MUC1 binding polypeptides and uses thereof." This invention demonstrates the potential of circulating auto-antibodies as biomarkers for early cancer detection. The methods developed utilize glycopeptide baits derived from human mucins to differentiate between cancer patients and healthy individuals.

Career Highlights

Throughout his career, Hans H Wandall has worked with various companies, including Go Therapeutics, Inc. and Velico Medical, Inc. His work has been instrumental in advancing cancer research and developing new therapeutic approaches.

Collaborations

Wandall has collaborated with notable individuals in the field, including Henrik Clausen and Eric Paul Bennett. These collaborations have contributed to the success of his research and innovations.

Conclusion

Hans H Wandall's contributions to cancer research through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in cancer detection and therapy.